Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis

Abstract

Introduction

Regulatory compliance is crucial in the clinical development of psychedelic substances, including psilocybin. This study aimed to examine the alignment of clinical trial protocols for psilocybin in the treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD) with established regulatory requirements.

Methods

A cross-sectional investigation was conducted on ClinicalTrials.gov using the keywords: “Psilocybin” and “Psilocin” to identify interventional studies with posted trial protocols. Only protocols for MDD and TRD were included. Data extraction focused on key regulatory aspects, including safety, functional unblinding, expectancy bias, and the distribution of investigational medical products.

Results

Eleven psilocybin trial protocols were identified, with four meeting the inclusion criteria. The most commonly studied psilocybin dose was 25 mg. Two trials were double-blind. Although the analyzed protocols superficially adhered to regulatory requirements, there were gaps in addressing potential drug interactions, the acute and chronic concurrent use of antidepressants, and prohibited medications. Certain aspects, such as functional unblinding or expectancy bias, did not share all pathways. Risk mitigation strategies were primarily based on external criteria. Patients with bipolar spectrum disorders or schizoaffective disorders were excluded.

Discussion

This study underscores the importance of conducting clinical trials on psychedelics in strict adherence to regulatory standards. Future research should focus on improving regulatory compliance and exploring the efficacy of psychedelics in broader patient populations.

Keywords

psilocybin - regulatory compliance - major depressive disorder - treatment-resistant depression

Publication History

Received: 21 July 2024

Accepted: 17 January 2025

Article published online:
17 April 2025

• References

• 1 Marx W, Penninx BWJH, Solmi M. et al. Major depressive disorder. Nat Rev Dis Primers 2023; 9: 44
• 2 Hasin DS, Sarvet AL, Meyers JL. et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 2018; 75: 336-346
• 3 McIntyre RS, Alsuwaidan M, Baune BT. et al. Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry 2023; 22: 394-412
• 4 Chen T, Cheng L, Ma J. et al. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. Pharmacol Res 2023; 194: 106837
• 5 Ko K, Knight G, Rucker JJ. et al. Psychedelics, mystical experience, and therapeutic efficacy: A systematic review. Front Psychiatry 2022; 13: 917199
• 6 Golden TL, Magsamen S, Sandu CC. et al. Effects of setting on psychedelic experiences, therapies, and outcomes: A rapid scoping review of the literature. Curr Top Behav Neurosci 2022; 56: 35-70
• 7 McCartney AM, McGovern HT, De Foe A. Predictors of psychedelic experience: A thematic analysis. J Psychoactive Drugs 2023; 55: 411-419
• 8 Heal DJ, Smith SL, Belouin SJ. et al. Psychedelics: Threshold of a therapeutic revolution. Neuropharmacology 2023; 236: 109610
• 9 Guo Q, Guo L, Wang Y. et al. Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs. Psychiatry Res 2024; 339: 116018
• 10 Rosenblat JD, Meshkat S, Doyle Z. et al. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med 2024; 5: 190-200.e5
• 11 Agrawal M, Richards W, Beaussant Y. et al. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer 2024; 130: 1137-1146
• 12 de Veen BT, Schellekens AF, Verheij MM. et al. Psilocybin for treating substance use disorders?. Expert Rev Neurother 2017; 17: 203-212
• 13 Lea JM, Michael K, Felix B. et al. Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design. Neurosci Appl 2022; 1: 100104 https://www.sciencedirect.com/science/article/pii/S2772408522001041
• 14 van Gerven J, Bonelli M. Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. Br J Clin Pharmacol 2018; 84: 1401-1409
• 15 Boesen K, Gøtzsche PC, Ioannidis JPA. EMA and FDA psychiatric drug trial guidelines: Assessment of guideline development and trial design recommendations. Epidemiol Psychiatr Sci 2021; 30: e35
• 16 Rivera-García MT, Cruz SL. The resurgence of hallucinogen drugs in clinical research. Rev Invest Clin 2023; 75: 169-178
• 17 Winkelman M. Psychedelics as medicines for substance abuse rehabilitation: Evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Curr Drug Abuse Rev 2014; 7: 101-116
• 18 Pisano VD, Putnam NP, Kramer HM. et al. The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol 2017; 31: 606-613
• 19 Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry. Accessed June 24, 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations
• 20 Clinical Investigation of Medicinal Products in the Treatment of Depression – Scientific Guideline. European Medicines Agency. Accessed June 24, 2024. https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-depression-scientific-guideline
• 21 Dodd S, Norman TR, Eyre HA. et al. Psilocybin in neuropsychiatry: A review of its pharmacology, safety, and efficacy. CNS Spectr 2022; 1-11
• 22 Rosenblat JD, Husain MI, Lee Y. et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force report: Serotonergic psychedelic treatments for major depressive disorder. Can J Psychiatry 2023; 68: 5-21
• 23 Gukasyan N, Davis AK, Barrett FS. et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol 2022; 36: 151-158
• 24 Kaminski D, Reinert JP. The tolerability and safety of psilocybin in psychiatric and substance-dependence conditions: A systematic review. Ann Pharmacother 2023; 10600280231205645
• 25 Hinkle JT, Graziosi M, Nayak SM. et al. Adverse events in studies of classic psychedelics: A systematic review and meta-analysis. JAMA Psychiatry 2024; 81: 1225-1235
• 26 Breeksema JJ, Kuin BW, Kamphuis J. et al. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol 2022; 36: 1100-1117
• 27 Colcott J, Guerin AA, Carter O. et al. Side-effects of mdma-assisted psychotherapy: A systematic review and meta-analysis. Neuropsychopharmacology 2024; 49: 1208-1226
• 28 Greif A, Šurkala M. Compassionate use of psychedelics. Med Health Care Philos 2020; 23: 485-496
• 29 Perez Rosal SR, La Torre JT, Birnkammer S. et al. Expert recommendations for Germany's integration of psychedelic-assisted therapy. BMC Med Educ 2024; 24: 1202
• 30 Adams DR, Allen H, Nicol GE. et al. Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science. Transl Behav Med 2024; 14: 744-752
• 31 Adam WL, Alan KD. What Matters Most in Psychedelic-Assisted Psychotherapy? Psychiatric Times. July 22, 2024; https://www.psychiatrictimes.com/view/what-matters-most-in-psychedelic-assisted-psychotherapy
• 32 Armstrong SB, Davis AK. Psychedelic research at a crossroads. Science 2024; 385: 1255
• 33 Calder A, Hasler G. Extrapharmacological safety topics in psychedelic-assisted psychotherapy. JAMA Psychiatry 2023; 80: 761-762
• 34 Goodwin GM, Malievskaia E, Fonzo GA. et al. Must psilocybin always “assist psychotherapy”?. Am J Psychiatry 2024; 181: 20-25
• 35 Gründer G, Brand M, Mertens LJ. et al. Treatment with psychedelics is psychotherapy: Beyond reductionism. Lancet Psychiatry 2024; 11: 231-236
• 36 Schenberg EE, King F, da Fonseca JE. et al. Is poorly assisted psilocybin treatment an increasing risk?. Am J Psychiatry 2024; 181: 75-76
• 37 Earleywine M, De Leo J, Bhayana D. et al. Psilocybin without psychotherapy: A cart without a horse?. Am J Psychiatry 2024; 181: 78-79
• 38 Hayes C, Wahba M, Watson S. Will psilocybin lose its magic in the clinical setting?. Ther Adv Psychopharmacol 2022; 12 20451253221090822
• 39 Rucker JJ. Evidence versus expectancy: The development of psilocybin therapy. BJPsych Bull 48: 110-117
• 40 Hovmand OR, Poulsen ED, Arnfred S. et al. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. J Psychopharmacol 2023; 37: 649-659
• 41 Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A. et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998; 9: 3897-3902
• 42 Good Clinical Practice. European Medicines Agency. 2024; https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-clinical-practice
• 43 Belouin SJ, Averill LA, Henningfield JE. et al. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology 2022; 219: 109214
• 44 Aaronson ST, van der Vaart A, Miller T. et al. Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: A nonrandomized open-label trial. JAMA Psychiatry 2024; 81: 555-562